A Phase 1 interventional study of Digoxin plus BI 10773 and Digoxin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-17.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to investigate the relative bioavailability of digoxin after concomitant multiple oral administration of BI 10773 and a single dose of digoxin in comparison to digoxin given alone to healthy male and female subjects.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Healthy male and female subjects
Exclusion criteria:
-Any relevant deviation from healthy conditions
Tablet, oral administration with 240 mL water
Drug: Digoxin
Tablets, oral administration with 240 mL water
Drug: Digoxin plus BI 10773
Drug pages: Digoxin · Empagliflozin
Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
Digoxin 0.5 mg as single dose
Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity.
Time frame: 1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose
Digoxin: Maximum Measured Concentration (Cmax)
Maximum measured concentration of digoxin, per period.
Time frame: 1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose
Digoxin: Area Under the Curve 0 to Last Quantifiable Data Point (AUC0-tz)
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to the time of the last quantifiable data point.
Time frame: 1.5 hours (h) prior to the first dose and 20 minutes (min), 40 min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, 72h, 96h after the first dose
| Milestone | Study Total |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
| Milestone | Study Total |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
| Milestone | Study Total |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to infinity.
| ng-h/mL | Digoxin Alone | Digoxin and Empa |
|---|---|---|
| Digoxin: Area Under the Curve 0 to Infinity (AUC0-∞) | 37.8 ± 23.2 | 39.9 ± 26.0 |
Maximum measured concentration of digoxin, per period.
| ng/mL | Digoxin Alone | Digoxin and Empa |
|---|---|---|
| Digoxin: Maximum Measured Concentration (Cmax) | 1.97 ± 43.3 | 2.25 ± 33.8 |
Area under the concentration-time curve of digoxin in plasma over the time interval from 0 extrapolated to the time of the last quantifiable data point.
| ng*h/mL | Digoxin Alone | Digoxin and Empa |
|---|---|---|
| Digoxin: Area Under the Curve 0 to Last Quantifiable Data Point (AUC0-tz) | 24.8 ± 24.8 | 28.4 ± 24.3 |
Collected over First administration of trial medication until 7 days after last administration of trial medication for Digoxin and BI 10773 + Digoxin, 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Digoxin Alone | — | 0/20 (0%) | 2/20 (10%) |
| Digoxin and Empa | — | 0/20 (0%) | 0/20 (0%) |
| Event | Digoxin Alone | Digoxin and Empa |
|---|---|---|
| FatigueGeneral disorders | 2/20 | 0/20 |
| Age, Continuous(years) | Study Total |
|---|---|
| Mean | 34.3 ± 8.1 |
| Sex: Female, Male(Participants) | Study Total |
|---|---|
| Female | 9 |
| Male | 11 |
The record gives a start of Feb 2011 and a primary completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Digoxin · Empagliflozin